Clinical Trial Update: NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating NEPA plus olanzapine with a dexamethasone-sparing strategy for chemotherapy-induced nausea and vomiting in patients receiving highly em…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• NEPA (netupitant/palonosetron)
• olanzapine (olanzapine)

Snippet

Sponsor: Fudan University | Conditions: Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy | Phase 3 | Status: COMPLETED